Academia to Industry

Like Judith Britz,1 I left the academic career path 15 years ago, for economic reasons. I left academics, it did not leave me: the papers I wrote 15 years ago are still being cited. I loved the science, but after five years living on $5,000 a year, the grim economic prospects and high career risk associated with academic science disqualified it from serious consideration. Risk is supposed to be associated with reward, but that's another subject. Do something with me: Take out a dollar bill and l

Written byJudson Jones
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Do something with me: Take out a dollar bill and look at it. It bears the likeness of our first president, the signature of the secretary of the treasury, the great seal of the United States, and quite a few other political symbols. It's a political document.

Money is our mechanism for the collective expression of value. If you're doing something people find valuable, they will tell you about it, using that mechanism. On the other hand, if you're doing something nobody cares about, you won't be rewarded for it.

Money is more than just money; it's a message. If you're not making any money, get the message. The world will never know, nor will it ever care about, the brilliant papers I never wrote. Nor will I. I am convinced that I am well-placed in the service of my fellow man. I am delighted by the intellectual challenges and ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies